bisoprolol has been researched along with captopril in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alberti, A; Bracchetti, D; Brunelli, A; Cantelli, I; Gradnik, R; Leonardi, G; Orselli, L; Pavesi, PC | 1 |
| Díez, J; Laviades, C; Mayor, G | 1 |
| Barbagallo, M; Dominguez, LJ; Jacober, SJ; Jacobs, DB; Sowers, JR | 1 |
| de Groot, M; Dienesch, C; Ertl, G; Horn, M; Hu, K; Hügel, S; Neubauer, S; Remkes, H | 1 |
| Frick, M; Gouya, G; Hügel, H; Pachinger, O; Pölzl, G; Ulmer, H | 1 |
| Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K | 1 |
| Abdel-Megied, AM; Belal, F; El Deeb, S; Elbarbry, FA; Grochovuy, T; Kovalenko, S; Logoyda, L; Magdy, G; Oleshchuk, O; Piponski, M | 1 |
1 review(s) available for bisoprolol and captopril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for bisoprolol and captopril
| Article | Year |
|---|---|
A double-blind comparison of bisoprolol and captopril for treatment of essential hypertension in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; Captopril; Double-Blind Method; Female; Humans; Hypertension; Male; Propanolamines; Quality of Life; Surveys and Questionnaires | 1990 |
Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Captopril; Double-Blind Method; Humans; Hypertension; Insulin Resistance; Middle Aged; Receptor, Insulin | 1997 |
14 other study(ies) available for bisoprolol and captopril
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Effects of antihypertensive therapy on left ventricular hypertrophy of essential hypertension: a role for insulin-like growth factor I?
Topics: Adult; Aged; Antihypertensive Agents; Bisoprolol; Captopril; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Insulin-Like Growth Factor I; Male; Middle Aged; Regression Analysis | 1993 |
Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolol; Body Weight; Captopril; Creatine; Creatine Kinase; Energy Metabolism; Isoenzymes; Male; Myocardial Infarction; Myocardium; Organ Size; Phosphocreatine; Rats; Rats, Wistar; Reference Values; Ventricular Function, Left | 1999 |
[Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Austria; Bisoprolol; Captopril; Cardiac Care Facilities; Data Interpretation, Statistical; Diuretics; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Neurotransmitter Agents; Practice Guidelines as Topic; Regression Analysis; Spironolactone; Stroke Volume | 2002 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan | 2005 |
LC-MS/MS bioanalytical method for the quantitative analysis of nifedipine, bisoprolol, and captopril in human plasma: Application to pharmacokinetic studies.
Topics: Bisoprolol; Captopril; Chromatography, Liquid; Humans; Male; Nifedipine; Reproducibility of Results; Tandem Mass Spectrometry | 2023 |